Third Harmonic Bio is going to shut down, should shareholders accept a plan by directors to liquidate the San Francisco ...

Shares of Third Harmonic Bio, Inc. (THRD) drew investor attention on Monday after the company announced that its board of ...

Third Harmonic Bio (NASDAQ:THRD) will be liquidating the company and selling its remaining assets, the company said on Monday ...

Third Harmonic Bio has abandoned plans to take its chronic spontaneous urticaria (CSU) drug into phase 2, instead preparing ...

The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it ...

San Francisco, USA-based inflammatory disease biotech Third Harmonic Bio (Nasdaq: THRD) saw its shares rocket almost 40% to $5.09 as the company revealed an orderly exit plan.

Third Harmonic Bio Inc (NASDAQ:THRD) shares are soaring on Monday after the company announced a plan of liquidation and dissolution.

Third Harmonic Bio (THRD) announced that the company’s board of directors, after considering opportunities to maximize stockholder value, has ...

On April 10, the Board of Directors unanimously approved the dissolution and liquidation of the Company, subject to stockholder approval, ...

expected in the third quarter of 2025 Sale of the Company’s assets, including THB335, to be initiated pending stockholder approval of the Plan of Liquidation and Dissolution Notwithstanding the ...

Third Harmonic Bio (NASDAQ:THRD) will be liquidating the company and selling its remaining assets, the company said on Monday. The California-based pharma company will be selling its assets ...

SAN FRANCISCO, April 14, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD) today announced that the Company’s board of directors, after considering opportunities to maximize ...